ATE545422T1 - Beta-glycolipide als immunomodulatoren - Google Patents

Beta-glycolipide als immunomodulatoren

Info

Publication number
ATE545422T1
ATE545422T1 AT06809778T AT06809778T ATE545422T1 AT E545422 T1 ATE545422 T1 AT E545422T1 AT 06809778 T AT06809778 T AT 06809778T AT 06809778 T AT06809778 T AT 06809778T AT E545422 T1 ATE545422 T1 AT E545422T1
Authority
AT
Austria
Prior art keywords
ceramide
immunomodulators
relates
lactosyl
glycolipids
Prior art date
Application number
AT06809778T
Other languages
English (en)
Inventor
Yaron Ilan
Original Assignee
Enzo Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzo Biochem Inc filed Critical Enzo Biochem Inc
Application granted granted Critical
Publication of ATE545422T1 publication Critical patent/ATE545422T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
AT06809778T 2005-11-24 2006-10-23 Beta-glycolipide als immunomodulatoren ATE545422T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL172175A IL172175A0 (en) 2005-11-24 2005-11-24 Beta glycolipids as immuno-modulators
PCT/IL2006/001217 WO2007060652A1 (en) 2005-11-24 2006-10-23 Beta glycolipids as immuno-modulators

Publications (1)

Publication Number Publication Date
ATE545422T1 true ATE545422T1 (de) 2012-03-15

Family

ID=37813589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809778T ATE545422T1 (de) 2005-11-24 2006-10-23 Beta-glycolipide als immunomodulatoren

Country Status (8)

Country Link
US (1) US7897580B2 (de)
EP (1) EP1957083B1 (de)
JP (1) JP2009517378A (de)
CN (1) CN101384268A (de)
AT (1) ATE545422T1 (de)
CA (1) CA2630935C (de)
IL (3) IL172175A0 (de)
WO (1) WO2007060652A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
JP2007533632A (ja) * 2003-09-30 2007-11-22 エンゾー セラピューティクス， インコーポレイテッド 疾患のグルコセレブロシド処理
ES2393674T3 (es) * 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
IL178821A0 (en) * 2006-05-25 2007-07-04 Ilan Yaron Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids
IL187959A0 (en) * 2007-12-06 2008-12-29 Haim Lotan Beta glycolipids for the treatment of calcification related degenerative disorders
AU2009205265A1 (en) 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
NZ571856A (en) * 2008-10-09 2011-02-25 Fonterra Corporate Res And Dev Ltd Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
ES2581523T3 (es) 2009-09-01 2016-09-06 Lz Therapeutics, Inc. Producción en cultivo celular (no bovino, no porcino) de GM1
WO2011146804A2 (en) * 2010-05-20 2011-11-24 Lazarus Therapeutics, Inc. Gm3 ganglioside replacement therapy
JP5967754B2 (ja) * 2011-05-02 2016-08-10 興人ライフサイエンス株式会社 酵母エキス抽出残渣の利用法
WO2013049220A1 (en) * 2011-09-30 2013-04-04 University Of Southern California Novel vaccination strategies or therapeutic treatment for influenza virus
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
US20170035791A1 (en) * 2014-04-14 2017-02-09 Natural Shield Israel 2016 Ltd Combination of beta-glucosylceramide and polyethoxylated castor oil and other adjuvants for controling blood sugar levels, immunoprotection and hepatoprotection
CN104383528B (zh) * 2014-10-24 2016-08-24 江苏省农业科学院 猪流行性腹泻灭活疫苗及其制备方法
EP3478279A4 (de) * 2016-06-29 2020-03-04 Hadasit Medical Research Services And Development Kombinationen von beta-glycolipiden und 4-[(2-amino-3,5-dibromphenyl)methylamino]cyclohexan-1-ol, zusammensetzungen und verwendungen davon zur behandlung von störungen im zusammenhang mit proteinfehlfaltungen und proteinaggregationen
WO2024028834A1 (en) * 2022-08-05 2024-02-08 Carbocode S.A. Reduction of signs of skin aging

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6422893A (en) * 1987-06-26 1989-01-25 Solco Basel Ag Drug composition, lactosyl compound and its production
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
FR2728707A1 (fr) * 1994-12-22 1996-06-28 Alcatel Postal Automation Syst Dispositif de lecture d'un code a barres pour une installation de tri postal
EP1049477A1 (de) * 1997-12-30 2000-11-08 A+ Science Invest AB Galactosylceramide, glucosylceramide, lactosylceramide, und spezifische fänger für diese zur verwendung in der prophylaxe oder therapie der prädiabetes, diabetes und/oder damit zusammenhängender komplikationen
AUPP675898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of activating t cells and agents useful for same
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005014008A2 (en) 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells

Also Published As

Publication number Publication date
CN101384268A (zh) 2009-03-11
IL250832B (en) 2019-03-31
IL191627A0 (en) 2008-12-29
EP1957083A1 (de) 2008-08-20
WO2007060652A1 (en) 2007-05-31
US20070117778A1 (en) 2007-05-24
IL172175A0 (en) 2011-08-01
IL250832A0 (en) 2017-04-30
EP1957083B1 (de) 2012-02-15
US7897580B2 (en) 2011-03-01
CA2630935C (en) 2014-08-12
CA2630935A1 (en) 2007-05-31
IL191627A (en) 2017-03-30
JP2009517378A (ja) 2009-04-30

Similar Documents

Publication Publication Date Title
ATE545422T1 (de) Beta-glycolipide als immunomodulatoren
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EA201170005A1 (ru) Диаминопиридиновые, пиримидиновые и пиридазиновые модуляторы гистаминового рецептора h
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
EA200800763A1 (ru) Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
EA200970765A1 (ru) 2-аминопиримидиновые модуляторы рецептора hгистамина
SG162747A1 (en) Erythropoietin receptor peptide formulations and uses
EA201490911A1 (ru) Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина
ZA200702375B (en) Quinazolines useful as modulators of ion channels
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.